Understanding the genetic basis of multiple sclerosis (MS) remains a major challenge, despite decades of intensive research. In order to identify candidate non-MHC susceptibility regions to MS, the results of whole genome screens for linkage or association and follow-up studies in 18 different populations were superimposed together in a combined genomic map. Analysis of this map led to the prediction of at least 38 potential susceptibility regions, each showing linkage and/or association in several populations. Among these, 17 regions were the most reproducibly reported in these studies, thus representing top predicted candidates for MS. This non-formal approach to meta-analysis demonstrated the ability to verify results and retrieve lost information in an association study. Assessment of the map in a Northern Irish refined screen (n ¼ 415 cases, n ¼ 490 controls) revealed association in 15 regions (Po0.05), including 10 promising candidates on chromosomes 1p13, 2p13, 2q14, 3p23, 7q21, 13q14, 15q13, 17p13, 18q21 and 20p12 (Po0.0025). Seven of these regions were previously overlooked in the Northern Irish whole genome association study. Collating results from numerous studies, this draft map represents a tool that should facilitate the analysis of the genetic backgrounds of MS in many populations.
Introduction
Association of HLA antigens with multiple sclerosis (MS) was reported several decades ago. 1 Since then, whole genome linkage studies have been carried out in different populations including, American, 2, 3 Australian, 4 British, 5, 6 Canadian, 7, 8 Finnish, 9 French, 2 Italian, 10 Sardinian, 11 Scandinavian 12 and Turkish. 13 These studies used low-density linkage mapping panels averaging 400 microsatellite markers at 10 Mb spacing. In addition, an improved linkage screen has been carried out in families of Northern European descent, using a highdensity linkage mapping panel of 5858 single nucleotide polymorphisms (SNPs).
14 On the other hand, a consortium of research groups from 15 countries in Europe and Australia performed 19 simultaneous whole genome screens for association with MS, in a large collaborative study known as Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES). 15 A panel of 6000 microsatellite markers was genotyped in separately pooled DNA samples from a case-control cohort in each population. Although most studies indicated the presence of a susceptibility locus in the MHC region on chromosome 6p21, there was little agreement about other suggested regions. These findings have been confirmed in metaanalyses of all the microsatellite-based linkage and association studies. 16, 17 Association analysis may represent an effective approach for the detection of susceptibility loci to complex genetic diseases, due to their relatively weak effects and complex interactions with other loci and environmental factors. 18 However, an informative association study requires, careful definition of patient phenotypes, well-matched samples, a large data set, a panel of genetic markers offering high-resolution coverage of the genome, consideration of the allele stratification of markers in the normal population and a cost-effective and accurate genotyping technology. 19 Unfortunately, some of these factors limit the power of association studies to detect susceptibility loci with moderate to modest effects. However, due to the rapid progress in the discovery and genotyping technology of SNPs, studies involving thousands of subjects and marker panels of several hundred thousands SNPs will be feasible in the near future.
In the meantime, meta-analysis of data from different populations may enhance the outcomes of individual association studies. However, due to the extensive inter and intra-population genetic heterogeneity of complex diseases such analysis may be problematic, as association in one population is not necessarily true in another. 19 Combining results from different populations may highlight a few shared susceptibility loci (such as the MHC locus) but significantly reduce if not eliminate the effects of other loci 'unassociated' in several populations. Another possible approach to such analysis is to locate genomic regions containing cumulative evidence of association, by superimposing results from different populations to produce a combined genomic map. Although, it provides a non-formal meta-analysis, this strategy maintains the independent results of participating populations, which reduces the impact of genetic heterogeneity. Here, we describe the deployment of this mapping strategy to predict candidate susceptibility regions to MS, using the results of 38 whole genome screens and follow-up studies for linkage or association, and the assessment of these regions in a refined genomic screen for association.
Subjects and methods

MS linkage, association and follow-up studies
The results of 13 linkage and 19 association whole genome screens and six follow-up studies were used to construct a combined genomic map of potential susceptibility loci to MS in 18 different populations. The populations, density of marker-panel and size of data sets described in these studies are summarized in Tables 1 and 2 . To avoid discrepancies, the genomic locations of the microsatellite markers reported in all studies were revised using the map viewer of the National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) and the human genome build 35.1.
Subjects
All participants are Caucasians of a Northern Irish descent. Patients (n ¼ 415) were diagnosed with clinically definite relapsing remitting MS according to the recommended diagnostic criteria for MS, 27, 28 with a mean Kurtzke expanded disability severity score (EDSS) of 5.7, a median age of disease onset of 29 and a female/male sex ratio of 2.5:1. The control group (n ¼ 490) consisted of anonymous blood donors, spouses or friends of MS patients (unrelated to MS patients) and laboratory personnel, with a female/male ratio of 1.2:1 and a median age of 30. The study was ethically approved and informed consent was obtained from participants before genetic analysis.
Microsatellite genotyping and statistical analysis Microsatellite markers were amplified using a multiplex PCR kit following the manufacturer's instructions 29 Markers were tested for association using a w 2 test in a series of 2 Â 2 and 2 Â m contingency tables, generated by 'clumping' the counts of certain groups of alleles together. Tests were carried out by clumping the count of each rare allele (expected value p5) together with the next rare allele (T1) or the individual alleles were tested against the total of all others (T4). In addition to these program default tests, the counts of minor alleles (frequencyo5%) were clumped together (T2) or the top two alleles showing a change in frequency were tested against the total of all others (T3). This stepwise analysis was used to improve the w 2 value by neutralizing the effect of the variable number of alleles and distribution of allele frequencies of microsatellite markers. These features may introduce inconsistencies when analyzing the data of a panel of microsatellite markers using a single statistical test.
Results
A combined genomic map of MS was constructed using 170 microsatellite markers or regions previously reported in whole genome linkage screens 2-14 and their follow-up studies, [20] [21] [22] [23] [24] [25] and 263 'top-ranked' markers reported in the case-control association studies of the GAMES project. 15 These markers or regions were selected based on the statistics reported in the original studies, including both significant and suggested occurrences. Some of the linkage screens and follow-up studies contained significant overlapping of data sets with pivotal screens (Table 1) . However, these studies included assessment of potential regions reported in other populations or used additional families and new markers, representing an important source of extra information that complements these initial linkage screens.
In two parallel analyses, a sliding window of 20 Mb for linkage and 5 Mb for association was used to screen the map for genomic regions showing linkage and/or association in several populations, as indicated by the presence of clustering of candidate markers. Of the 433 markers used, 95 linked and 69 associated markers mapped within such regions. The remaining markers were scattered through out the genome and were excluded as possible population-specific or false positives. Each of these regions was also supported by a number of 'low-ranked' GAMES markers (empirical Po0.05) which were not included in the final lists of promising markers in several populations (http:// www.gene.cimr.cam.ac.uk/MSgenetics/GAMES/). In addition to the MHC region, the analyses predicted at least 38 potential non-MHC susceptibility regions ( Figure 1 ). Seventeen of these regions have been reported in five or more different populations, representing top predicted candidates for MS on chromosomes 1p34, 1q43-44, 3p26-25, 3q13, 5q14, 5q31, 7q21, 9p21, 11p15, 11q23, 17p13, 17q23, 18p11, 19p13, 19q13, 20p12 and 22q12. The strongest clustering of markers was observed in the MHC region on chromosome 6p21 followed by a region on chromosome 9p21 ( Figure 2 ).
To examine the ability of this non-formal approach to meta-analysis to predict susceptibility loci to MS, the combined MS map was assessed in a refined Northern. Irish genomic screen for association. Owing to the localized nature of association reports and higher density of the marker panel used in the GAMES project, the preference was given to the top-ranked GAMES markers in charting these 38 predicted regions. The clustering pattern of these markers was used to identify the potential boundaries of each region, where a number of markers were selected for further analysis. Twenty-five well-defined regions were selected for assessment. The remaining 13 regions, which mainly relied on evidence from linkage studies, spanned extended genomic distances and were reserved for future analysis. To cover every potential region in the Northern Irish population, an additional eight regions previously reported in the Northern Irish GAMES study were also included in the analysis. 30 In total, 140 microsatellite markers, including several in each region, were analyzed by individual genotyping in the same cohort of samples (n ¼ 200 cases, n ¼ 200 controls) comprised the DNA pools previously used in the Northern Irish GAMES study. These included 19 Northern Irish non-MHC top-ranked markers and markers associated with other populations or required to cover gaps in the selected regions. Of these, 20 markers produced significant results in at least one of the four statistical tests carried out (Po0.05, data not Combined results from two independent genomic screens. Significant markers from both screens were assessed in the refined analysis.
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H Abdeen et al shown). These markers were selected for further analysis by genotyping in another cohort of samples (n ¼ 215 cases, n ¼ 290 controls). The total genotyping success rate was above 98%. The second cohort showed patterns of allele frequencies consistent with those of the initial cohort.
To allow the detection of moderate to weak non-MHC associations, data was analyzed with and without a correction for multiple testing (Table 3) . Using the combined results of the two cohorts, 10 markers showed association with the disease, on chromosomes 1p13, 2p13, 2q14, 3p23, 7q21, 13q14, 15q13, 17p13, 18q21 and 20p12. These markers produced P-values that would remain significant, in at least one statistical test, after correction for the number of markers investigated in the second stage of this refined screen (Po0.0025) but not for the number of tests performed for each marker. Without correction, an additional five markers showed association on chromosomes 3q13, 5p13, 5q14, 11q23 and 19p13 (Po0.05 in at least two tests). In total, 15 of the 33 regions investigated showed evidence of association (Figure 2) . Most of the markers identified showed a significant change in the frequencies of two alleles. Accordingly, the T3 statistic (comparing the counts of the top two alleles against the total of all others) was considered the most informative of all statistical tests. Following this refined genomic screen, association in many predicted regions remains questionable until analyzed in other populations. Four of the 11 investigated top predicted candidates failed to show association; however, there was a tendency toward significance in case of chromosomes 9p21 and 19q13 (Figure 2 , P T4 ¼ 0.059 and 0.057, respectively). On the other hand, six of the extra Northern Irish regions included in the analysis showed association and were added to the finalized genomic map; while, others which failed to show association in the Northern Irish population and did not contain plausible evidence in other populations were excluded.
Discussion
Genetic heterogeneity of complex diseases is a consequence of the continuous evolution of the human genome, which complicates meta-analysis of association studies from different populations. 32 Historical events such as recombination, admixture and selection impose a dynamic haplotype block structure on the genome, which varies between ethnically diverse populations. 32 Likewise, ancestral susceptibility regions are expected to undergo extensive rearrangements, causing complex diseases to become associated, in different populations, with variable sets of markers or alleles of the same markers, moving further away from susceptibility variants. It is also highly likely that a number of susceptibility loci have evolved independently in different 
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populations. This led to a situation where susceptibility regions are likely to display inter-and intra-population geographical variations in type, frequency and associated markers, as evidenced in the case of the MHC association. 33, 34 However, these variable sets of associated markers remain closely clustered on the genome, a feature that could be used to localize a susceptibility region.
Another possible non-formal approach to meta-analysis is to superimpose results from different populations in a combined genomic map. The map could be then used to identify potential susceptibility regions, as characterized by the presence of clustering of associated markers throughout several populations, or within the same population in regions retaining extended linkage disequilibrium (LD) with susceptibility variants. This mapping approach offers several advantages. First, the results of participating populations remain independent, which reduces the deleterious effect of genetic heterogeneity. On the contrary, heterogeneity may play a beneficial role by presenting a wider variety of associated markers, which enhances the clustering patterns in many susceptibility regions. Second, associations should be detectable over longer genomic distances than the average extent of association in individual populations, which may compensate for the poor coverage of the genome using the available low-density panels of markers. Third, analysis of data from several populations should help to filter out false positives and identify regions containing deceptive negatives in the individual studies. Finally, the clustering patterns of markers could be used to localize the potential boundaries and cores of many regions, where LD with susceptibility variants is likely to be stronger.
The publication of a large number of whole genome linkage and association studies with MS offered an excellent opportunity to put this hypothesis to the test. These studies produced an enormous set of data in an unprecedented number of populations for any complex disease. In an attempt to construct a genomic map of potential susceptibility regions, which allows verifying results and retrieval of lost information in individual association studies, the results of whole genome screens for linkage or association and follow-up studies were combined in two parallel meta-analyses. Most of the linkage studies were low-powered due to the number of families involved, 16 while GAMES studies were limited by the low-density of the marker panel, the size of the data sets, the use of a DNA pooling approach and the emphasis on the top-ranked markers in each population excluding others. 35 However, the use of this mapping approach to perform the analyses helped to overcome some of the limitations of these studies, allowing the prediction of many potential regions. Indeed, these analyses excluded almost two thirds the reported markers, which did not fall in clusters, as possible population-specific or false positives. The remaining markers formed clusters in several regions, which extended over genomic distances long enough to be detectable using the few markers identified in these lowresolution genomic screens. The best example is the MHC region, which extends over a 3 Mb of chromosome 
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These include regions previously reported in the Norhtern Irish GAMES study and others predicted by the meta-analyses (underlined). The P-values that would survive a correction for the number of markers included in the second stage of the study are underlined (Po0.0025).
Further evidence used to support these regions includes the number of GAMES markers, linkage reports and populations suggested to be involved in each region. Non-significant. (Figure 2) . Furthermore, the associations identified in the Northern Irish refined screen are located between 0.3 and 4.0 Mb away from other associations in the same regions. This indicates the utility of the mapping approach to reconstruct association patterns over long genomic distances in regions sharing a possible common ancestry in several populations. As expected, the strongest predicted region on the MS map was around the confirmed MHC region. This region contains extensive clustering of markers associated in all populations, with the exception of the Southern and Eastern European populations of Hungary, Italy, Sardinia and Turkey, which did not show linkage or association in the region. 10, 11, 13, 15 Associations seem to extend between markers D6S265 and TAP1. Each marker is associated in only a subgroup of populations indicating the presence of variations in LD patterns in the region. Several populations such as the British, Australian and Belgian are associated with more than one marker suggesting the existence of extended LD with susceptibility variant(s). The dense clustering of markers between TNFa and TAP1 leads to the assumption that a susceptibility variant(s) exists in this interval. This agrees with the evidence of strong association in the MHC class II region between markers G511525 and D6S2444. 36, 37 In addition, the analyses predicted at least 38 potential non-MHC susceptibility regions (Figure 1 ). Of these, 17 regions have been reported in the linkage and/or GAMES studies in five or more different populations, such as chromosomes 7q21, 2, 4, 7, 14, 15, 20 17q23, 5, 9, 14 19q13, 2, 9, 15, 20 and 20p12, 4, 14, 15 and appear to account for several linkage and association reports in each population. The importance of some of these top predicted candidates has been emphasized in previous formal 16 and non-formal 17 and 22q12. 25 Furthermore, seven of these regions showed association following this refined genomic screen in the Northern Irish population, on chromosomes 3q13, 5q14, 7q21, 11q23, 17p13, 19p13 and 20p12. Detection of the MHC region, particularly its core around the MHC class II gene cluster, and other previously reported candidate regions confirms the ability of these meta-analyses to predict susceptibility regions to MS. Refined genomic screening using the MS map revealed a much higher number of candidate regions in the Northern Irish population than was previously reported. 30 Fifteen regions showed association, including eight previously reported and seven new candidate associations which were completely overlooked in the Northern Irish GAMES study (Table 3) . Six new candidate regions were added to the map on chromosomes 2p13, 2q14, 3p23, 5p13, 13q14 and 15q14 (Figure 2 ). Although, they may appear specific to the Northern Irish population, many of these regions contain several lowranked GAMES markers in other populations and the region on chromosome 2p13 has been previously indicated in a meta-analysis of linkage studies. 16 On the other hand, a new candidate region showed association on chromosome 1p13. This region is particularly interesting; unlike other new candidates, which were previously indicated in the Northern Irish GAMES study, it was identified using the sole evidence obtained from the map. Although new to MS, chromosome 1p13 has been established as a general susceptibility region to many other human autoimmune diseases. 41 As concluded by all previous studies, the current study excludes the presence of a major non-MHC susceptibility locus to MS. The combined MS genomic map contains at least 17 top predicted candidate regions. On the other hand, the top markers identified in the Northern Irish population showed similar changes in allele frequencies (on average 10.3% of the total number of alleles). This indicates the possibility that these regions are more or less equally involved in the genetic background of the disease, at least in the Northern Irish population. However, the observed changes in allele frequencies of some markers such as D1S487, D2S347 and D2S1779 (14.0, 13.4 and 12.3% of the total number of alleles, respectively) are encouraging compared to TNFa, an MHC marker strongly associated in the Northern Irish population (16.8%). 42 Most of the regions identified in this refined genomic screen contain genes with key roles in neuronal development, survival and regeneration that could be easily involved in susceptibility to MS (Table 3) . Chromosome 1p13 contains at least two candidate genes, NGFB and PTPN22. The NGFB gene encodes the nerve growth factor, beta subunit, which is involved in the regulation of growth and differentiation of neurons with an important role in axonal regeneration after injury. 43 The PTPN22 gene encodes a lymphoid protein tyrosine kinase, a negative regulator of T-cell activation involved in susceptibility to several autoimmune diseases such as rheumatoid arthritis and type 1 diabetes mellitus. 44 Although the functional variant (R620W) in that gene did not show association with MS, 44 further analysis may unveil other associated variants. CNTNAP5 on chromosome 2q14 encodes a contactin associated like protein.
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Contactin is a member of the immunoglobulin cell adhesion molecules (Ig-CAMs) localized on neuronal membranes, with key functions in axogenesis and myelination. 45 CHRNA7 on chromosome 15q13 encodes the cholinergic receptor, neuronal nicotinic, alpha polypeptide 7, a major component of brain nicotinic receptors required for attenuation of inflammatory responses in the nervous system by inhibition of macrophage TNF release. 46 NTN1 on chromosome 17p13 encodes netrin, which plays a role in the developing nervous system by promoting both axonal outgrowth and guidance. 47 In addition, NCAM1 on chromosome 11q23 encodes neural cell adhesion molecule 1, which regulates neurite outgrowth, fasciculation and target recognition in the developing nervous system and suggested to play an important role in regeneration and learning in the adult nervous system. 48 While, GDNF on chromosome 5p13 encodes glial cell line-derived neurotrophic factor, a nerve growth factor with similar functions as NGFB. 43 Furthermore, ADAM22 on chromosome 7q21 and ADAMTS10 on chromosome 19p13 both encode members of the disintegrin and metalloproteases family, involved in the formation of neural connections in the developing central nervous system. 49 There are also a number of genes encoding immunoregulatory and signaling proteins and their receptors such as TGFA, TGFBR, TNFRSF11A, TNFRSF12, TNFRSF13, IL-18 and Susceptibility regions to MS H Abdeen et al IL-10RA, which may contribute to the immune responses observed during the disease course. On the other hand, there are excellent candidate genes in many of the top predicted regions unassociated with MS in the Northern Irish population. The most striking example is FLJ31810 on chromosome 9p21, a homologue of the LRRN6A gene which encodes the leucine rich repeat neuronal 6C protein (LRRN6C). 50 LRRN6C is similar to other neuronal LRR proteins, a family of transmembrane receptors preferentially expressed in the nervous system and involved in axonal guidance and migration and nervous system development and regeneration. 50 Remarkably, the six top-ranked GAMES markers identified in this region clustered within or around that gene suggesting a possible important role in MS.
It is important to keep in mind that, the few markers identified in linkage and association studies and this refined screen cannot describe the strength and patterns of LD or rank these regions. To localize the haplotype blocks containing strongest LD with susceptibility variants and identify candidate genes, each region should be reanalyzed using a high-density panel of markers. These haplotype blocks range from a few to around 150 kb in size, 32 and can only be localized using a panel of hundreds to thousands of SNPs and/or tens to hundreds of microsatellite markers. On the other hand, to carry out similar refined screens in other populations, it is important to analyze several markers in each of the top 17 predicted candidates, which appear to contribute significantly to the genetic backgrounds of MS in many populations, in addition to any other regions potentially associated in each population.
A genomic map of potential susceptibility regions to MS was constructed using non-formal meta-analyses of linkage and association studies. These analyses emphasized the importance of at least 17 previously reported regions and identified a number of new candidates. Using this map, we were able to unravel evidence of association in a significantly higher number of regions than was initially reported in the Northern Irish whole genome screen. This indicates the ability of the mapping strategy to retrieve information that might have been lost due to limitations in an association study. Based on numerous studies, this map should be of a great help to investigate susceptibility regions in other populations. This refined analysis of the human genome should produce a clearer image of MS susceptibility regions, a first step towards the identification of the genes implicated in the disease process.
